Arcus Biosciences
RCUS
75 hedge funds and large institutions have $235M invested in Arcus Biosciences in 2019 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 33 increasing their positions, 19 reducing their positions, and 10 closing their positions.
74% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 19
12% more capital invested
Capital invested by funds: $210M → $235M (+$24.8M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3.07% less ownership
Funds ownership: 59.37% → 56.29% (-3.1%)
4% less funds holding
Funds holding: 78 → 75 (-3)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| 1 |
BlackRock
New York
|
+$5.35M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$2.75M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.43M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$2.41M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.24M |
Top Sellers
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$10.9M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.9M |
| 3 |
AG
Artal Group
Luxembourg
|
-$2.15M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$877K |
| 5 |
Morgan Stanley
New York
|
-$707K |
RCUS Hedge Fund Activity: Q3 2019 in Review
75 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q3 2019, worth a combined $235M — up 12% from $210M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of RCUS and 8 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 33 added.
The largest buyer was BlackRock, adding an estimated $5.35M. The largest seller was Foresite Capital Management III, exiting entirely with an estimated $10.9M sold.
- 75 institutional investors held Arcus Biosciences (RCUS) as of Q3 2019, down from 78 in Q2 2019.
- Funds reported $235M of Arcus Biosciences stock for Q3 2019, up 12% quarter-over-quarter.
- 8 funds opened new Arcus Biosciences positions in Q3 2019 and 10 closed out, a net change of -2 holders.
- The largest Arcus Biosciences buyer in Q3 2019 was BlackRock, an estimated $5.35M added.
- The largest Arcus Biosciences seller in Q3 2019 was Foresite Capital Management III, an estimated $10.9M sold.
Based on aggregated 13F filings for Q3 2019.